Hint mode is switched on Switch off

PTC Therapeutics, ordinary share
PTCT, US69366J2006

Add a stock to WL
Choose all Reset all
PTC Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
PTC Therapeutics is a US pharmaceutical company focused on the development of small molecule, orally administered treatments for orphan diseases.
  • Issuer
  • Full borrower / issuer name
    PTC Therapeutics, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    PTCT
  • Placement
    20.06.2013
  • Lock up period
    180
  • Number of papers
    8,372,000
  • Volume of raised funds
    125.58 mln USD
  • Final placement price
    15 USD
  • Price change since placement date
    373.13%
  • By capitalization
    355.17 mln USD

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide

Related Stock indices

Indicators

News

08/05/2026 PTC Therapeutics (PTCT) Beats Q1, Raises 2026 Revenue Guidance
24/03/2026 PTC Therapeutics: Regulation Fd Disclosure, Financial Statements And Exhibits
19/02/2026 PTC Therapeutics: Item7.01.regulation Fd Disclosure, Regulation Fd Disclosure, Financial Statements And Exhibits
12/02/2026 PTC Therapeutics: Of This Report, Including Exhibit 99.1 Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Expressly Set Forth By Specific Reference In Such A Filing. All Website Addresses Given In This Report Or Incorporated Herein By Reference Are For Information Only And Are Not Intended To Be An Active Link Or To Incorporate Any Website Information Into This Report, Financial Statements And Exhibits
12/01/2026 PTC Therapeutics: This Current Report On Form 8k And Exhibits 99.1 And 99.2 Include A Forwardlooking Financial Measure That Was Not Prepared In Accordance With Accounting Principles Generally Accepted In The United States (gaap), Nongaap R&d And Sg&a Expenses (which Excludes Noncash Stockbased Compensation Expense). Management Uses This Measure When Assessing And Identifying Operational Trends And, In Management’s Opinion, This Nongaap Measure Is Useful To Investors And Other Users Of Its Financial Statements By Providing Greater Transparency Into The Historical And Projected Operating Performance Of The Company And The Company’s Future Outlook. Nongaap Financial Measures Are Not An Alternative For Financial Measures Prepared In Accordance With Gaap, Financial Statements And Exhibits
All organization news

Domestic and international bonds of the issuer

Holders

Industry Leaders

Registration is required to get access.